Psoriasis

Is ustekinumab superior to etanercept for psoriasis?

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe psoriasis found that ustekinumab was superior to high-dose etanercept over a 12-week period; however, several questions remain to be addressed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Schön, M. P. & Boehncke, W. H. Psoriasis. N. Engl. J. Med. 352, 1899–1912 (2005).

    Article  Google Scholar 

  2. 2

    Gottlieb, A. B. et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175, 2721–2729 (2005).

    CAS  Article  Google Scholar 

  3. 3

    Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183–3194 (2007).

    CAS  Article  Google Scholar 

  4. 4

    McKenzie, B. S., Kastelein, R. A. & Cua, D. J. Understanding the IL-23–IL-17 immune pathway. Trends Immunol. 27, 17–23 (2006).

    CAS  Article  Google Scholar 

  5. 5

    Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665–1674 (2008).

    CAS  Article  Google Scholar 

  6. 6

    Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).

    CAS  Article  Google Scholar 

  7. 7

    Schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat. Biotech. 26, 1317–1318 (2008).

    CAS  Article  Google Scholar 

  8. 8

    Griffiths, C. E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).

    CAS  Article  Google Scholar 

  9. 9

    Trial watch: Novel biologic for psoriasis shows superiority over current best-seller. Nat. Rev. Drug Discov. 7, 880–881 (2008).

  10. 10

    Gottlieb, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633–640 (2009).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Annegret Kuhn.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kuhn, A., Luger, T. Is ustekinumab superior to etanercept for psoriasis?. Nat Rev Rheumatol 6, 500–501 (2010). https://doi.org/10.1038/nrrheum.2010.134

Download citation

Further reading

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing